Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation

• Published in: Diabetes care Vol. 30; no. 2; pp. 372 - 374
• Main Authors: Geisler, Tobias, Anders, Nicole, Paterok, Maria, Langer, Harald, Stellos, Konstantinos, Lindemann, Stephan, Herdeg, Christian, May, Andreas E, Gawaz, Meinrad
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.02.2007
• Subjects: Acute coronary syndromes; Adenosine Diphosphate - pharmacology; Biological and medical sciences; Blood Platelets - drug effects; Blood Platelets - physiology; Cardiology. Vascular system; Cardiovascular disease; Care and treatment; Coronary Disease - therapy; Coronary heart disease; Coronary stenosis; Diabetes; Diabetes. Impaired glucose tolerance; Diabetic Angiopathies - therapy; Diagnosis; Drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Health aspects; Heart; Heart attacks; Humans; Informed consent; Medical sciences; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; Risk factors; Stents; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology; Ticlopidine - therapeutic use; Transplants & implants; Endocrinopathy; Human; Diabetes mellitus; Platelet function; Instrumentation therapy; Cardiovascular disease; Clopidogrel; Implantation; Thienopyridine derivative; Coronary heart disease; Stent; Antiplatelet agent
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc06-1625

Of these, 161 (33.2%) had diabetes, 264 (54%) underwent elective procedure for stable angina, and 221 (46.0%) were treated by PCI for acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, ST elevation myocardial infarction). In the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) (19,20), additional treatment of diabetic patients with the platelet glycoprotein IIb-IIIa blockade for coronary stenting resulted in a reduction of 6-month death and myocardial infarction rate from 12.7 to 6.2% compared with stent placebo.